pO2 polarography versus positron emission tomography ([ 18F] fluoromisonidazole, [18F]-2-fluoro-2′- deoxyglucose): An appraisal of radiotherapeutically relevant hypoxia

Strahlentherapie und Onkologie

Volumn 180, Issue 10, 2004, Pages 616-622

  Gagel, Bernd ^a   Reinartz, Patrick ^b   DiMartino, Ercole ^b   Zimny, Michael ^b   Pinkawa, Michael ^a   Maneschi, Payam ^a   Stanzel, Sven ^a   Hamacher, Kurt ^c   Coenen, Heinz H ^c   Westhofen, Michael ^b   Büll, Ulrich ^b   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

Author keywords

FDG; FMISO; pO2 polarography; Positron emission tomography; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; NITROIMIDAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DRUG UPTAKE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IMAGING SYSTEM; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; OXYGEN TENSION; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TISSUE OXYGENATION; TUMOR HYPOXIA;

CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MISONIDAZOLE; OXIMETRY; OXYGEN; OXYGEN CONSUMPTION; POLAROGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 5444228799     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-004-1229-y     Document Type: Article

References (26)

1. 18F-fluorinated tracers and positron emission tomography. Acta Oncol 2000;39:629-37.
2. Chapman JD, Engelhardt EL, Stobbe CC, et al. Measuring hypoxia and predicting tumor radio resistance with nuclear medicine assays. Radiother Oncol 1998;46:229-37.
3. Chapman JO, Schneider RF, Urbain JL, et al. Single-photon emission computed tomography assays for tissue oxygenation. Semin Radiat Oncol 2001; 11:47-57.
4. Dunst J, Stadler P, Becker A, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179:521-6.
5. Evans NTS, Naylor PFD. The effect of oxygen breathing and radiotherapy upon tissue oxygen tension of some human tumors. Br J Radiol 1963;36:418-25.
6. Gray LH, Conger AD, Ebert M. The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-42.
7. 3H-misonidazole labeling and viability of hypoxic cells in the sandwich system, an in vitro tumor analogue. Int J Radiat Oncol Biol Phys 1989;16:143-53.
8. Hlatky L, Alpen EL. Two dimensional diffusion limited system for cell growth. Cell Tissue Kinet 1985;18:597-611.
9. Höckel M, Schleger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
10. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18] fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992;22:199-212.
11. Kubota K, Tada M, Yamada S, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999;26:750-7.
12. Mathias CJ, Welch MJ, Kilbourn MR, et al. Radiolabeled hypoxic cell sensitizers: tracers for assessment of ischemia. Life Sci 1987;41:199-206.
13. McManus ME, Monks A, Collins JM, et al. Nonlinear pharmacokinetics of misonidazole and desmethylmisonidazole in the isolated perfused rat liver. J Pharmacol Exp Ther 1981;219:669-74.
14. Minn H, Clavo C, Wahl RL. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation of PET imaging. Nucl Med Biol 1996;23:941-6.
15. Muelter-Klieser W, Schlenger KH, Walenta S, et al. Pathophysiological approaches to identify tumor hypoxia in patients. Radiother Oncot Suppl 1991;20:21-8.
16. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80.
17. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
18. Prekeges JL, Rasey JS, Grunbaum Z, et al. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991;42:2387-95.
19. Raleigh JA. Hypoxia and its clinical significance In: Tepper JE, Raleigh JA, eds. Seminars in radiation oncology, vol 6. Orlando: Saunders, 1996:1-70.
20. 18F] fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996;36:417-28,
21. Rasey JS, Koh WJ, Grierson JR, et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17:985-91.
22. Schäfer U, Micke O, Müller SB, et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-34.
23. Stone HB, Brown JM, Philips TL, et al. Oxygen in human tumors: correlations between methods of measurements and response to therapy. Radiat Res 1993;136:422-34.
24. Thews O, Vaupel P. Relevant parameters for describing the oxygenation status of solid tumors. Strahlenther Onkol 1996;172:239-42.
25. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynaecologic tumors: what is the optimal haemoglobin level? Strahlenther Onkol 2002; 178:727-31.
26. Zimny M, Schröder W, Wolters S, et al. 18-F Fluordeoxyglukose PET beim Ovarialkarzinom: Methodik und erste Ergebnisse. Nuklearmedizin 1997; 36:228-33.